miR‐155 is involved in tumor progression of mycosis fungoides
Citations Over TimeTop 10% of 2013 papers
Abstract
Abstract Biopsy specimens from 23 early stage and 19 tumor‐stage mycosis fungoides (MF) patients were evaluated for miR‐155 expression by real‐time qualitative PCR and compared with 15 biopsy specimens from patients with T‐cell‐rich inflammatory skin diseases. Significant upregulation of miR‐155 was found in MF tumors compared with both early‐stage MF lesions and controls. There was no difference in miR‐155 expression between early‐stage and inflammatory dermatoses. Using laser capture microdissection, it was found that miR‐155 was significantly higher in the lymphoma cells in tumor stage compared with the intraepidermal lymphocytes in early stage. In contrast, there was no difference in miR‐155 expression between the intraepidermal lymphocytes and the dermal lymphocytes in early‐stage MF. These findings suggest that although miR‐155 expression cannot serve to discriminate early‐stage MF from inflammatory dermatoses; however, it is involved in the switch from the indolent early stage into the aggressive tumor stage of the disease.
Related Papers
- → Cyclosporine in the treatment of cutaneous T cell lymphoma(1990)25 cited
- → ADVANCES IN THE MANAGEMENT OF CUTANEOUS T-CELL LYMPHOMA(1998)16 cited
- → Cutaneous T-cell lymphoma (mycosis fungoides)(1996)9 cited
- → Efficacy of chlormethine gel in patients with stage I–IIA mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): re-analysis of a randomized phase 2 study(2019)
- → Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe study(2019)